首页> 外文期刊>Expert opinion on investigational drugs >Potential breakthroughs with investigational drugs for hairy cell leukemia
【24h】

Potential breakthroughs with investigational drugs for hairy cell leukemia

机译:毛细胞白血病研究药物的潜在突破

获取原文
获取原文并翻译 | 示例
       

摘要

Introduction: Hairy cell leukemia (HCL) is a rare subtype of B-cell chronic lymphoid leukemia. It is characterized by progressive pancytopenia, splenomegaly and infiltrations of the bone marrow, liver and spleen. Over the last few years, several new immunological drugs, particularly immunotoxins, BRAF inhibitors and B-cell receptor (BCR) pathway inhibitors have been developed and investigated as potential treatment options.
机译:简介:毛细胞白血病(HCL)是B细胞慢性淋巴白血病的一种罕见亚型。它的特征是进行性全血细胞减少,脾肿大和骨髓,肝脏和脾脏的浸润。在过去的几年中,已经开发了几种新的免疫药物,特别是免疫毒素,BRAF抑制剂和B细胞受体(BCR)途径抑制剂,并作为潜在的治疗选择进行了研究。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号